CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Poseida Therapeutics, Inc. - PSTX CFD

3.33
0.6%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.05
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.026262 %
Charges from full value of position ($-4.99)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026262%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.00404 %
Charges from full value of position ($0.77)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.00404%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 3.31
Open 3.35
1-Year Change 74.48%
Day's Range 3.22 - 3.58
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jul 12, 2024 3.33 -0.01 -0.30% 3.34 3.59 3.20
Jul 11, 2024 3.31 0.32 10.70% 2.99 3.37 2.99
Jul 10, 2024 2.95 0.03 1.03% 2.92 3.00 2.90
Jul 9, 2024 2.95 0.03 1.03% 2.92 3.00 2.91
Jul 8, 2024 2.95 -0.03 -1.01% 2.98 3.06 2.92
Jul 5, 2024 2.97 0.07 2.41% 2.90 2.97 2.82
Jul 3, 2024 2.91 -0.07 -2.35% 2.98 3.06 2.89
Jul 2, 2024 3.00 0.06 2.04% 2.94 3.16 2.93
Jul 1, 2024 2.98 0.15 5.30% 2.83 3.03 2.68
Jun 28, 2024 2.89 0.28 10.73% 2.61 2.96 2.61
Jun 27, 2024 2.69 0.25 10.25% 2.44 2.70 2.39
Jun 26, 2024 2.45 -0.09 -3.54% 2.54 2.58 2.42
Jun 25, 2024 2.56 -0.14 -5.19% 2.70 2.73 2.55
Jun 24, 2024 2.72 -0.06 -2.16% 2.78 2.86 2.70
Jun 21, 2024 2.76 0.10 3.76% 2.66 2.93 2.64
Jun 20, 2024 2.62 0.01 0.38% 2.61 2.92 2.54
Jun 18, 2024 2.62 -0.17 -6.09% 2.79 2.79 2.61
Jun 17, 2024 2.79 0.08 2.95% 2.71 2.81 2.71
Jun 14, 2024 2.74 0.00 0.00% 2.74 2.79 2.68
Jun 13, 2024 2.82 0.10 3.68% 2.72 2.85 2.72

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Poseida Therapeutics, Inc. Company profile

About Poseida Therapeutics Inc

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on utilizing its genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure. It is developing a portfolio of product candidates in a variety of indications based on its core platforms, including its non-viral piggyBac DNA Delivery System, Cas-CLOVER site-specific gene editing system and nanoparticle- and AAV-based gene delivery technologies. The Company's product candidate portfolio includes P-BCMA-101, P-PSMA-101, P-BCMA-ALLO1, P-MUC1C-ALL01, Dual CAR, P-OTC-101 and P-MMUT-101. Its lead product candidate, P-BCMA-101, is an autologous CAR-T targeting B cell maturation antigen (BCMA). P-PSMA-101 is an autologous CAR-T product candidate targeting prostate-specific membrane antigen (PSMA), being developed to treat patients with metastatic castrate resistant prostate cancer (mCRPC).

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Poseida Therapeutics Inc revenues increased from $0K to $31.2M. Net loss decreased 4% to $125M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Interest expense decrease of 4% to $3.4M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$2.10 to -$2.01.

Industry: Bio Therapeutic Drugs

9390 Towne Centre Drive
Suite 200
SAN DIEGO
CALIFORNIA 92121
US

People also watch

XRP/USD

0.54 Price
-1.210% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

US100

20,336.40 Price
+0.570% 1D Chg, %
Long position overnight fee -0.0263%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 7.0

ETH/USD

3,200.84 Price
+1.010% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

Gold

2,411.42 Price
-0.180% 1D Chg, %
Long position overnight fee -0.0191%
Short position overnight fee 0.0109%
Overnight fee time 21:00 (UTC)
Spread 0.60

Still looking for a broker you can trust?

Join the 630,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading